care clinics semaglutide reviews reddit Best Online Tirzepatide Compounding Providers Compared For 2026 The weight-loss drug Wegovy lowered
Description
This is not incremental improvement over existing therapies

Across the STEP trials, onceweekly subcutaneous semaglutide 2.4 mg was consistently associated with mean weight losses of 14.9%17.4% in participants without diabetes, and improvements in cardiometabolic risk factors, physical function and quality of life

In March 2024, FDA approved a new indication to reduce MACE in adults with established CV disease and overweight/obesity based on SELECT, marking the first obesity medication with a dedicated CV riskreduction label in this population
95% CI, 0.831.01)

Some users report mood swings, anxiety, or low mood on Wegovy due to rapid hormone changes and calorie restriction

Phase III trials are planned, consisting of four placebo-controlled studies involving 5,000 to 7,000 patients, including those with type 2 diabetes and hypertension
